PURPOSE: We developed a precision medicine program for patients with advanced cancer using integrative whole-exome sequencing and transcriptome analysis. PATIENTS AND METHODS: Five hundred fifteen patients with locally advanced/metastatic solid tumors were prospectively enrolled, and paired tumor/normal sequencing was performed. Seven hundred fifty-nine tumors from 515 patients were evaluated. RESULTS: Most frequent tumor types were prostate (19.4%), brain (16.5%), bladder (15.4%), and kidney cancer (9.2%). Most frequently altered genes were TP53 (33%), CDKN2A (11%), APC (10%), KTM2D (8%), PTEN (8%), and BRCA2 (8%). Pathogenic germline alterations were present in 10.7% of patients, most frequently CHEK2 (1.9%), BRCA1 (1.5%), BRCA2 (1.5%), and MSH6 (1.4%). Novel gene fusions were identified, including a RBM47-CDK12 fusion in a metastatic prostate cancer sample. The rate of clinically relevant alterations was 39% by whole-exome sequencing, which was improved by 16% by adding RNA sequencing. In patients with more than one sequenced tumor sample (n = 146), 84.62% of actionable mutations were concordant. CONCLUSION: Integrative analysis may uncover informative alterations for an advanced pan-cancer patient population. These alterations are consistent in spatially and temporally heterogeneous samples.
PURPOSE: We developed a precision medicine program for patients with advanced cancer using integrative whole-exome sequencing and transcriptome analysis. PATIENTS AND METHODS: Five hundred fifteen patients with locally advanced/metastatic solid tumors were prospectively enrolled, and paired tumor/normal sequencing was performed. Seven hundred fifty-nine tumors from 515 patients were evaluated. RESULTS: Most frequent tumor types were prostate (19.4%), brain (16.5%), bladder (15.4%), and kidney cancer (9.2%). Most frequently altered genes were TP53 (33%), CDKN2A (11%), APC (10%), KTM2D (8%), PTEN (8%), and BRCA2 (8%). Pathogenic germline alterations were present in 10.7% of patients, most frequently CHEK2 (1.9%), BRCA1 (1.5%), BRCA2 (1.5%), and MSH6 (1.4%). Novel gene fusions were identified, including a RBM47-CDK12 fusion in a metastatic prostate cancer sample. The rate of clinically relevant alterations was 39% by whole-exome sequencing, which was improved by 16% by adding RNA sequencing. In patients with more than one sequenced tumor sample (n = 146), 84.62% of actionable mutations were concordant. CONCLUSION: Integrative analysis may uncover informative alterations for an advanced pan-cancerpatient population. These alterations are consistent in spatially and temporally heterogeneous samples.
Authors: Andrew D Cherniack; Hui Shen; Vonn Walter; Chip Stewart; Bradley A Murray; Reanne Bowlby; Xin Hu; Shiyun Ling; Robert A Soslow; Russell R Broaddus; Rosemary E Zuna; Gordon Robertson; Peter W Laird; Raju Kucherlapati; Gordon B Mills; John N Weinstein; Jiashan Zhang; Rehan Akbani; Douglas A Levine Journal: Cancer Cell Date: 2017-03-13 Impact factor: 31.743
Authors: Samuel J Klempner; Sai-Hong Ignatius Ou; Daniel B Costa; Paul A VanderLaan; Eric M Sanford; Alexa Schrock; Laurie Gay; Siraj M Ali; Vincent A Miller Journal: Clin Lung Cancer Date: 2015-03-26 Impact factor: 4.785
Authors: T Ueda; Y Nakata; N Yamasaki; H Oda; K Sentani; A Kanai; N Onishi; K Ikeda; Y Sera; Z-I Honda; K Tanaka; M Sata; S Ogawa; W Yasui; H Saya; J Takita; H Honda Journal: Oncogene Date: 2016-02-01 Impact factor: 9.867
Authors: Dan R Robinson; Yi-Mi Wu; Robert J Lonigro; Pankaj Vats; Erin Cobain; Jessica Everett; Xuhong Cao; Erica Rabban; Chandan Kumar-Sinha; Victoria Raymond; Scott Schuetze; Ajjai Alva; Javed Siddiqui; Rashmi Chugh; Francis Worden; Mark M Zalupski; Jeffrey Innis; Rajen J Mody; Scott A Tomlins; David Lucas; Laurence H Baker; Nithya Ramnath; Ann F Schott; Daniel F Hayes; Joseph Vijai; Kenneth Offit; Elena M Stoffel; J Scott Roberts; David C Smith; Lakshmi P Kunju; Moshe Talpaz; Marcin Cieślik; Arul M Chinnaiyan Journal: Nature Date: 2017-08-02 Impact factor: 49.962
Authors: Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan Journal: Cell Date: 2018-06-14 Impact factor: 41.582
Authors: Rajen J Mody; Yi-Mi Wu; Robert J Lonigro; Xuhong Cao; Sameek Roychowdhury; Pankaj Vats; Kevin M Frank; John R Prensner; Irfan Asangani; Nallasivam Palanisamy; Jonathan R Dillman; Raja M Rabah; Laxmi Priya Kunju; Jessica Everett; Victoria M Raymond; Yu Ning; Fengyun Su; Rui Wang; Elena M Stoffel; Jeffrey W Innis; J Scott Roberts; Patricia L Robertson; Gregory Yanik; Aghiad Chamdin; James A Connelly; Sung Choi; Andrew C Harris; Carrie Kitko; Rama Jasty Rao; John E Levine; Valerie P Castle; Raymond J Hutchinson; Moshe Talpaz; Dan R Robinson; Arul M Chinnaiyan Journal: JAMA Date: 2015-09-01 Impact factor: 56.272
Authors: Francesca Demichelis; Heidi Greulich; Jill A Macoska; Rameen Beroukhim; William R Sellers; Levi Garraway; Mark A Rubin Journal: Nucleic Acids Res Date: 2008-02-27 Impact factor: 16.971
Authors: David C Wilkes; Verena Sailer; Hui Xue; Hongwei Cheng; Colin C Collins; Martin Gleave; Yuzhuo Wang; Francesca Demichelis; Himisha Beltran; Mark A Rubin; David S Rickman Journal: Cold Spring Harb Mol Case Stud Date: 2017-05-03
Authors: Vincenza Conteduca; Sheng-Yu Ku; Loredana Puca; Megan Slade; Luisa Fernandez; Judy Hess; Rohan Bareja; Panagiotis J Vlachostergios; Michael Sigouros; Juan Miguel Mosquera; Andrea Sboner; David M Nanus; Olivier Elemento; Ryan Dittamore; Scott T Tagawa; Himisha Beltran Journal: Mol Cancer Ther Date: 2020-03-03 Impact factor: 6.261
Authors: Matthew J Mosquera; Sungwoong Kim; Rohan Bareja; Zhou Fang; Shuangyi Cai; Heng Pan; Muhammad Asad; Maria Laura Martin; Michael Sigouros; Florencia M Rowdo; Sarah Ackermann; Jared Capuano; Jacob Bernheim; Cynthia Cheung; Ashley Doane; Nicholas Brady; Richa Singh; David S Rickman; Varun Prabhu; Joshua E Allen; Loredana Puca; Ahmet F Coskun; Mark A Rubin; Himisha Beltran; Juan Miguel Mosquera; Olivier Elemento; Ankur Singh Journal: Adv Mater Date: 2021-11-14 Impact factor: 32.086
Authors: Tian Zhang; Anika Agarwal; R Garland Almquist; Daniella Runyambo; Sally Park; Elizabeth Bronson; Rengasamy Boominathan; Chandra Rao; Monika Anand; Taofik Oyekunle; Patrick Healy; Megan A McNamara; Kathryn Ware; Jason A Somarelli; Daniel J George; Andrew J Armstrong Journal: Biomark Res Date: 2021-02-18
Authors: Aram Vosoughi; Tuo Zhang; Kyrillus S Shohdy; Panagiotis J Vlachostergios; David C Wilkes; Bhavneet Bhinder; Scott T Tagawa; David M Nanus; Ana M Molina; Himisha Beltran; Cora N Sternberg; Samaneh Motanagh; Brian D Robinson; Jenny Xiang; Xiao Fan; Wendy K Chung; Mark A Rubin; Olivier Elemento; Andrea Sboner; Juan Miguel Mosquera; Bishoy M Faltas Journal: Nat Commun Date: 2020-12-03 Impact factor: 14.919
Authors: Miguel Gonzalez Velez; Heidi E Kosiorek; Jan B Egan; Andrea L McNatty; Irbaz B Riaz; Steven R Hwang; Glenn A Stewart; Thai H Ho; Cassandra N Moore; Parminder Singh; Renee K Sharpsten; Brian A Costello; Alan H Bryce Journal: Prostate Cancer Prostatic Dis Date: 2021-07-22 Impact factor: 5.455